Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Matthew Majewski
Advertisement
Articles by Matthew Majewski
There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Advertisement
Latest Updated Articles
- Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D
December 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
2
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD
5